Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 6.58B 987M 885M 818M 741M 1.38B 93.97B 1.4B 9.79B 3.9B 49.17B 3.7B 3.62B 156B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 5.74B 861M 772M 714M 647M 1.21B 82B 1.22B 8.54B 3.4B 42.91B 3.23B 3.16B 136B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.2%
Yield 2024 *
-
Yield 2025 -
27/08 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
27/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
14/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/01 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
28/10/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
26/08/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
04/06/25 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
27/05/25 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25/04/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
18/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
15/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
13/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
11/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day+1.37%
1 week-8.95%
Current month-19.18%
1 month-14.49%
3 months+2.43%
6 months-18.28%
Current year-3.91%
1 week 2.87
Extreme 2.87
3.09
1 month 2.87
Extreme 2.87
3.78
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 26/12/2022
Corporate Officer/Principal 42 18/04/2018
Corporate Officer/Principal 40 23/05/2019
Director TitleAgeSince
Director/Board Member 40 14/03/2025
Director/Board Member 53 11/11/2022
Director/Board Member 42 11/11/2022
Date Insider Type Main position Quantity % Market Cap. Importance
2/7/25 Sell 587,500 0.0283%
2/7/25 Sell

Director

259,600 0.0125%
2/7/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-8.95%-7.81%+21.40% 987M
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.56%+2.12%+53.76%+65.93% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+2.56%+2.51%+34.13%+56.11% 294B
+0.99%-0.74%+2.58%+26.09% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +1.22%+0.95%+36.21%+70.91% 403.81B
Weighted average by Cap. +1.16%+1.50%+44.84%+89.05%

Financials

2024 2025
Net sales 2.44B 366M 328M 304M 275M 514M 34.87B 520M 3.63B 1.45B 18.24B 1.37B 1.34B 57.92B 2.14B 320M 287M 266M 241M 450M 30.5B 455M 3.18B 1.27B 15.96B 1.2B 1.18B 50.68B
Net income 233M 34.91M 31.32M 28.96M 26.23M 49M 3.32B 49.59M 346M 138M 1.74B 131M 128M 5.52B 377M 56.53M 50.72M 46.89M 42.47M 79.34M 5.38B 80.3M 561M 223M 2.82B 212M 208M 8.94B
Net Debt -509M -76.3M -68.45M -63.29M -57.32M -107M -7.27B -108M -757M -301M -3.8B -286M -280M -12.07B -838M -126M -113M -104M -94.43M -176M -11.97B -179M -1.25B -497M -6.26B -472M -462M -19.89B
Projected Income Statement - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
28/10/26 CNY 2.950 +1.37% 142,305,478
27/10/26 CNY 2.910 -3.32% 118,166,342
26/10/26 CNY 3.010 -2.27% 136,398,152
23/10/26 CNY 3.080 +1.32% 203,469,986
22/10/26 CNY 3.040 -6.17% 242,267,717

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
  1. Stock Market
  2. Stocks
  3. 002437 Stock